Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Targeting of multidrug-resistant human ovarian carcinoma cells with anti-P-glycoprotein antibody conjugates.

Literature DB >> 22278817

Targeting of multidrug-resistant human ovarian carcinoma cells with anti-P-glycoprotein antibody conjugates.

Abstract

A monoclonal antibody (mAb) to P-glycoprotein (Pgp), UIC2, is used as a targeting moiety for N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer/drug [(meso chlorin e(6) mono(N-2-aminoethylamide) (Mce(6)) or doxorubicin (DOX)] conjugates to investigate their cytotoxicity towards the Pgp-expressing human ovarian carcinoma cell line A2780/AD. The binding, internalization, and subcellular trafficking of a fluorescein labeled UIC2 targeted HPMA copolymer are studied and show localization to the plasma membrane with limited internalization. The specificity of the UIC2-targeted HPMA copolymer/drug conjugates are confirmed using the sensitive cell line A2780 that does not express Pgp.

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：

Year: 2012 PMID： 22278817 PMCID： PMC4613759 DOI： 10.1002/mabi.201100350

Source DB: PubMed Journal: Macromol Biosci ISSN： 1616-5187 Impact factor: 4.979

76 in total

Review 1. Cytotoxic and cytostatic effects of antitumor agents induced at the plasma membrane level.

Authors: H Grunicke; J Hofmann
Journal: Pharmacol Ther Date: 1992 Impact factor: 12.310

Review 2. Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy.

Authors: David S Miller; Björn Bauer; Anika M S Hartz
Journal: Pharmacol Rev Date: 2008-06-17 Impact factor: 25.468

3. Complete inhibition of P-glycoprotein by simultaneous treatment with a distinct class of modulators and the UIC2 monoclonal antibody.

Authors: Katalin Goda; Ferenc Fenyvesi; Zsolt Bacsó; Henrietta Nagy; Teréz Márián; Attila Megyeri; Zoltán Krasznai; István Juhász; Miklós Vecsernyés; Gábor Szabó
Journal: J Pharmacol Exp Ther Date: 2006-10-18 Impact factor: 4.030

4. Monoclonal antibodies against P-glycoprotein, an MDR1 gene product, inhibit interleukin-2 release from PHA-activated lymphocytes.

Authors: G Raghu; S W Park; I B Roninson; E B Mechetner
Journal: Exp Hematol Date: 1996-08 Impact factor: 3.084

5. Preparation of Fab' from murine IgG2a for thiol reactive conjugation.

Authors: K D Fowers; J Callahan; P Byron; J I Kopecek
Journal: J Drug Target Date: 2001 Impact factor: 5.121

6. Actin disruption inhibits endosomal traffic of P-glycoprotein-EGFP and resistance to daunorubicin accumulation.

Authors: Dong Fu; Basil D Roufogalis
Journal: Am J Physiol Cell Physiol Date: 2006-11-22 Impact factor: 4.249

7. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line.

Authors: T Minko; P Kopecková; V Pozharov; J Kopecek
Journal: J Control Release Date: 1998-07-31 Impact factor: 9.776

8. Binding properties of monoclonal antibodies recognizing external epitopes of the human MDR1 P-glycoprotein.

Authors: A H Schinkel; R J Arceci; J J Smit; E Wagenaar; F Baas; M Dollé; T Tsuruo; E B Mechetner; I B Roninson; P Borst
Journal: Int J Cancer Date: 1993-09-30 Impact factor: 7.396

9. Accumulation of degradation products of doxorubicin and pirarubicin formed in cell culture medium within sensitive and resistant cells.

Authors: M Fiallo; A Laigle; M N Borrel; A Garnier-Suillerot
Journal: Biochem Pharmacol Date: 1993-02-09 Impact factor: 5.858

10. Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-CD44 interactions with small hyaluronan oligosaccharides.

Authors: Mark G Slomiany; Lu Dai; Paul A Bomar; Thomas J Knackstedt; D Alex Kranc; Lauren Tolliver; Bernard L Maria; Bryan P Toole
Journal: Cancer Res Date: 2009-05-26 Impact factor: 12.701

5 in total

Targeting of multidrug-resistant human ovarian carcinoma cells with anti-P-glycoprotein antibody conjugates.

Review 1. Cytotoxic and cytostatic effects of antitumor agents induced at the plasma membrane level.

Review 2. Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy.

3. Complete inhibition of P-glycoprotein by simultaneous treatment with a distinct class of modulators and the UIC2 monoclonal antibody.

4. Monoclonal antibodies against P-glycoprotein, an MDR1 gene product, inhibit interleukin-2 release from PHA-activated lymphocytes.

5. Preparation of Fab' from murine IgG2a for thiol reactive conjugation.

6. Actin disruption inhibits endosomal traffic of P-glycoprotein-EGFP and resistance to daunorubicin accumulation.

7. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line.

8. Binding properties of monoclonal antibodies recognizing external epitopes of the human MDR1 P-glycoprotein.

9. Accumulation of degradation products of doxorubicin and pirarubicin formed in cell culture medium within sensitive and resistant cells.

10. Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-CD44 interactions with small hyaluronan oligosaccharides.

Review 1. Design of smart HPMA copolymer-based nanomedicines.

2. Targeting ABCB1-mediated tumor multidrug resistance by CRISPR/Cas9-based genome editing.

3. Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance.

Review 4. Polymer-drug conjugates: origins, progress to date and future directions.

Review 5. Photoimmunotherapy of Ovarian Cancer: A Unique Niche in the Management of Advanced Disease.